Piramal Pharma

Which are the latest news on Piramal Pharma?

Why is Piramal Pharma Ltd falling/rising?

As of 05-Sep, Piramal Pharma Ltd's stock price is at 214.20, showing a slight decline after two days of gains. Despite a strong year-to-date performance, concerns about long-term financial health and recent disappointing results are impacting investor sentiment.

As of 05-Sep, Piramal Pharma Ltd's stock price is currently at 214.20, reflecting a slight decline of 0.25 or 0.12%. This decrease follows a trend reversal after two consecutive days of gains. The stock has shown a performance inline with its sector today, but it is also close to its 52-week high, being just 3.18% away from Rs 220.4.<BR><BR>In the short term, the stock has experienced a 2.01% decline over the past week, contrasting with a 5.83% increase over the past month. Year-to-date, the stock has performed well, with a notable increase of 24.32%, significantly outperforming the Sensex, which has declined by 10.21% during the same period. However, the long-term fundamentals raise concerns, as the company has reported a -9.27% CAGR growth in operating profits over the last five years, indicating weak long-term financial strength.<BR><BR>Moreover, the company has a high Debt to EBITDA ratio of 6.16 times, which suggests challenges in servicing its debt. The recent financial results have also been disappointing, with a reported PBT of Rs -96.87 crore, marking a drastic fall of -100.5% compared to the previous four-quarter average. This has contributed to a perception of the stock being overvalued, especially given its low Return on Capital Employed (ROCE) of 2.61% and a high Debt-Equity ratio of 0.70 times.<BR><BR>Despite the rising investor participation, as evidenced by a 110.22% increase in delivery volume against the 5-day average, the underlying financial weaknesses and recent negative results are likely contributing to the current decline in stock price.

Who are in the management team of Piramal Pharma?

The management team of Piramal Pharma includes Chairperson Nandini Piramal, CEO Peter D. DeYoung, CFO Vivek Valsaraj, and Directors Neeraj Bharadwaj and Nathalie Leitch, along with several independent directors and Company Secretary Tanya D'Costa. This team is responsible for the company's strategic direction and operations.

The management team of Piramal Pharma includes the following key individuals:<BR><BR>1. **Nandini Piramal** - Chairperson<BR>2. **Peter D. DeYoung** - Executive Director & CEO<BR>3. **Vivek Valsaraj** - Executive Director & CFO<BR>4. **Neeraj Bharadwaj** - Director<BR>5. **Nathalie Leitch** - Director<BR><BR>Additionally, the board features several independent directors:<BR>- **Jairaj Purandare**<BR>- **S. Rama Dorai**<BR>- **Peter Stevenson**<BR>- **Sridhar Gorthi**<BR>- **Vibha Paul Rishi**<BR><BR>Lastly, **Tanya D'Costa** serves as the Company Secretary and Compliance Officer. This team plays a crucial role in guiding the company's strategic direction and operations.

What does Piramal Pharma do?

Piramal Pharma Ltd is a small-cap pharmaceutical company established in 2020, offering a range of products and services with recent net sales of ₹2,270 Cr and a net loss of ₹69 Cr as of June 2026. The company has a market cap of ₹28,265 Cr and a debt-equity ratio of 0.53.

Overview:<BR>Piramal Pharma Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, offering a portfolio of differentiated products and services through comprehensive manufacturing capabilities.<BR><BR>History:<BR>Piramal Pharma Limited was incorporated on March 4, 2020, as a Public Limited Company. The latest quarterly results reported net sales and profit for the period ending June 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 2,270 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: -69 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 28,265 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.53 <BR>Return on Equity: -1.59% <BR>Price to Book: 3.57 <BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Who are the peers of the Piramal Pharma?

Piramal Pharma's peers include Emcure Pharma, Sai Life, Wockhardt, Neuland Labs, Acutaas Chemical, Pfizer, Granules India, Caplin Point Lab, and ERIS Lifescience. In terms of performance, Acutaas Chemical leads with a 1-year return of 124.38%, while Piramal Pharma has a return of 16.80%, which is above ERIS Lifescience's -27.88%.

Peers: The peers of Piramal Pharma are Emcure Pharma, Sai Life, Wockhardt, Neuland Labs., Acutaas Chemical, Pfizer, Granules India, Caplin Point Lab, and ERIS Lifescience.<BR><BR>Quality Snapshot: Excellent management risk is observed at Emcure Pharma, Neuland Labs., Acutaas Chemical, and Pfizer, while Average management risk is found at Sai Life, Wockhardt, and Piramal Pharma. Good growth is seen in Emcure Pharma, Neuland Labs., and Acutaas Chemical, while Average growth is noted at Sai Life, Wockhardt, Granules India, Caplin Point Lab, and ERIS Lifescience, with Piramal Pharma showing Below Average growth. Excellent capital structure is present in Sai Life, Neuland Labs., Acutaas Chemical, Pfizer, Granules India, and Caplin Point Lab, while Good capital structure is found at Emcure Pharma and ERIS Lifescience, with Piramal Pharma showing Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Acutaas Chemical at 124.38%, while the lowest is ERIS Lifescience at -27.88%. Piramal Pharma's 1-year return of 16.80% is higher than that of ERIS Lifescience but lower than that of Acutaas Chemical. Additionally, Pfizer and ERIS Lifescience are the only peers with negative six-month returns.

How big is Piramal Pharma?

As of 31st August, Piramal Pharma Ltd has a market capitalization of 28,265.00 Cr and reported net sales of 9,205.28 Cr with a loss of 313.63 Cr over the latest four quarters. Shareholder's funds are 8,162.62 Cr, and total assets are valued at 17,450.31 Cr.

As of 31st August, Piramal Pharma Ltd has a market capitalization of 28,265.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Piramal Pharma reported net sales of 9,205.28 Cr. However, the company experienced a loss of 313.63 Cr during the same period.<BR><BR>The latest annual reporting period for the balance sheet is March 2026. Shareholder's funds stand at 8,162.62 Cr, while total assets are valued at 17,450.31 Cr.

Are Piramal Pharma Ltd latest results good or bad?

Piramal Pharma Ltd's latest results show a significant net loss of ₹69.39 crore, reflecting deepening profitability challenges, despite a 17.39% year-on-year revenue growth. Overall, the mixed results indicate more negative trends, and investors should remain cautious.

Piramal Pharma Ltd's latest results present a mixed picture. On one hand, the company reported a consolidated net loss of ₹69.39 crore for Q1 FY27, which is a significant increase in losses compared to the previous quarter, reflecting a 685.84% decline QoQ. This indicates that the company's profitability challenges are deepening.<BR><BR>On the other hand, the company achieved a revenue growth of 17.39% year-on-year, with net sales reaching ₹2,269.92 crore. This growth was driven by demand in its Contract Development and Manufacturing Organisation (CDMO) and Consumer Healthcare segments. However, it is important to note that there was a sequential decline of 17.51% from the previous quarter, highlighting volatility in sales.<BR><BR>The operating margin improved to 8.60%, up 308 basis points year-on-year, but this is still significantly lower than the 16.74% margin achieved in the previous quarter. Additionally, the interest coverage ratio of 0.66x indicates that the company is struggling to meet its debt obligations, which raises concerns about its financial health.<BR><BR>Overall, while there are positive signs in terms of revenue growth and operational improvements, the widening losses and ongoing financial challenges suggest that the results are more negative than positive at this time. Investors should be cautious and monitor the company's ability to turn around its profitability in the coming quarters.

Should I buy, sell or hold Piramal Pharma Ltd?

Is Piramal Pharma technically bullish or bearish?

As of December 3, 2025, Piramal Pharma's technical trend has shifted to bearish, supported by negative indicators from MACD, moving averages, Bollinger Bands, and a lack of positive signals from RSI and OBV.

As of 3 December 2025, the technical trend for Piramal Pharma has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from multiple indicators. The weekly MACD is bearish, and the daily moving averages also reflect a bearish trend. Bollinger Bands confirm bearish conditions on both weekly and monthly time frames. The Dow Theory indicates a mildly bearish stance on the weekly and monthly charts. Overall, the lack of positive signals from the RSI and OBV further supports the bearish outlook.

How has been the historical performance of Piramal Pharma?

Piramal Pharma has shown a generally upward trend in net sales and operating profit from Mar'22 to Mar'25, despite fluctuations in profit before and after tax. Total liabilities and assets have increased, indicating growth, while cash flow has been variable.

Answer:<BR>The historical performance of Piramal Pharma shows a fluctuating yet generally upward trend in key financial metrics over the past few years.<BR><BR>Breakdown:<BR>Piramal Pharma's net sales have increased from 6,559.10 Cr in Mar'22 to 9,151.18 Cr in Mar'25, reflecting a consistent growth in total operating income, which mirrors the sales figures. The total expenditure has also risen, reaching 7,706.35 Cr in Mar'25, up from 5,609.44 Cr in Mar'22. Operating profit (PBDIT) has shown improvement, climbing from 1,225.46 Cr in Mar'22 to 1,579.64 Cr in Mar'25, with the operating profit margin increasing to 15.79% in Mar'25 from 14.48% in Mar'22. Despite this, profit before tax has been volatile, with a notable drop to -174.48 Cr in Mar'23 before recovering to 341.71 Cr in Mar'25. Profit after tax has also fluctuated, moving from a high of 316.93 Cr in Mar'22 to a loss of 240.79 Cr in Mar'23, and then to a modest profit of 18.20 Cr in Mar'25. The consolidated net profit reflects this trend, showing a recovery from -186.46 Cr in Mar'23 to 91.13 Cr in Mar'25. On the balance sheet, total liabilities increased from 12,499.77 Cr in Mar'22 to 15,284.46 Cr in Mar'25, while total assets rose correspondingly, indicating a growing scale of operations. Cash flow from operating activities has been variable, peaking at 1,004.00 Cr in Mar'24 before dropping to 892.00 Cr in Mar'25, with net cash outflow recorded in Mar'25. Overall, Piramal Pharma's financial performance demonstrates resilience and growth potential despite some fluctuations in profitability.

Is Piramal Pharma overvalued or undervalued?

As of November 27, 2025, Piramal Pharma is fairly valued with a PE ratio of -557.34, an EV to EBITDA of 24.82, and a Price to Book Value of 3.07, contrasting with peers like Sun Pharma and Cipla, while experiencing a year-to-date stock decline of 29.83% compared to the Sensex's gain of 9.70%.

As of 27 November 2025, Piramal Pharma's valuation grade has moved from expensive to fair. The company appears to be fairly valued at this time. Key ratios include a PE ratio of -557.34, an EV to EBITDA of 24.82, and a Price to Book Value of 3.07. <BR><BR>In comparison to its peers, Piramal Pharma's valuation stands out against Sun Pharma, which is considered expensive with a PE ratio of 37.62, and Cipla, which is rated attractive with a PE ratio of 22.67. Notably, Piramal's negative PE ratio indicates significant challenges, while its EV to EBITDA ratio is comparable to some peers but still reflects high leverage. Recent stock performance shows a decline of 29.83% year-to-date, contrasting sharply with the Sensex's gain of 9.70%, further emphasizing the company's current valuation context.

Who are the top shareholders of the Piramal Pharma?

The top shareholders of Piramal Pharma include the Sri Krishna Trust with 26.62%, foreign institutional investors holding 31.49%, and mutual funds with 12.73%. The highest public shareholder is Ca Alchemy Investments at 18%, while individual investors own 13.11%.

The top shareholders of Piramal Pharma include the promoters, who hold the majority of the shares. Specifically, the Sri Krishna Trust, represented by Mr. Ajay G. Piramal and Dr. (Mrs.) Swati A. Piramal, has the highest holding at 26.62%. <BR><BR>In addition to the promoters, foreign institutional investors (FIIs) hold a significant stake of 31.49%, while mutual funds are represented by 25 schemes, accounting for 12.73% of the shares. The highest public shareholder is Ca Alchemy Investments, which holds 18%. Individual investors collectively own 13.11% of the company.

When is the next results date for Piramal Pharma?

No Upcoming Board Meetings

Has Piramal Pharma declared dividend?

Piramal Pharma Ltd has declared a 1% dividend, amounting to ₹0.1 per share, with an ex-date of July 12, 2024. The dividend yield is 0.05%, and while the company has shown strong returns over the past year and two years, recent performance has been negative in the last six months.

Piramal Pharma Ltd has declared a 1% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1%<BR>- Amount per share: 0.1<BR>- Ex-date: Jul-12-2024<BR><BR>Dividend Yield: 0.05%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -22.43%, the dividend return was 0%, resulting in a total return of -22.43%.<BR><BR>Over the past year, the price return was 39.89%, the dividend return was 0.06%, leading to a total return of 39.95%.<BR><BR>In the 2-year period, the price return was 143.03%, the dividend return was 0.11%, which resulted in a total return of 143.14%.<BR><BR>For the 3-year period, both the price return and dividend return were 0%, resulting in a total return of 0.0%.<BR><BR>In the 4-year period, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>Over the last 5 years, the price return and dividend return remained at 0%, resulting in a total return of 0.0%.<BR><BR>Overall, while Piramal Pharma has declared a dividend, the returns over the past periods show significant variability, particularly with strong returns in the 1 and 2-year periods compared to negative returns in the recent 6-month period. The dividend yield is relatively low, indicating that while there is a dividend, it may not be a primary attraction for investors.